Last close As at 06/08/2026
GBP4.26
▲ −1.00 (−0.23%)
Market capitalisation
GBP95m
Content on this client is only available to investors based in the UK.
Please use the tick box below to confirm your location.
Investment Companies
Investment Companies
Research: Healthcare
The first set of 12-month data from the ongoing retinitis pigmentosa (RP) eye study has been released showing a stable longer-term response, which is excellent. However, the 12-month data are only for three patients so far with mean numbers reported. ReNeuron aims to present more RP eye data over 2020. Stroke data from the CTX PISCES III trial are expected around mid-2021. We retain the indicative value of ReNeuron at £197m.